Skin disease Archives

RDEB recessive dystrophic epidermolysis bullosa skin blisters

News and Trends 21 Nov 2022

New Replay HSV gene therapy company Telaria to focus on skin diseases

Replay has announced the launch of Telaria, a herpes simplex virus (HSV) gene therapy company targeting rare skin diseases. It is the second of Replay’s product companies to leverage its high payload capacity HSV delivery vector, synHSV. Telaria’s co-founders are HSV scientists, entrepreneurs, and specialists in genetic skin diseases. In addition to Joe Glorioso, Telaria’s […]

November 21, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

A new treatment for tackling epidermolysis bullosa

By Jordi Casals, president, EMEA, Amryt Pharma Epidermolysis bullosa (EB), sometimes described as “the worst disease you’ve never heard of,” is a group of rare and distressing inherited skin disorders primarily diagnosed in young children. The genetic mutations that cause EB can result in the skin being extremely fragile. Any physical contact with the skin […]

November 14, 2022 - 3 minutesmins - By External Contributor

News and Trends 11 Nov 2022

Prurigo nodularis treatment recommended for EU approval

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Dupixent (dupilumab) in the European Union (EU) to treat adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. Dupilumab is being jointly developed by Sanofi and Regeneron. The European Commission is expected […]

November 11, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 3 Oct 2022

Incyte to acquire Medicxi-backed Villaris Therapeutics to tackle vitiligo

Incyte has entered into an agreement to acquire Villaris Therapeutics, an asset-centric biopharmaceutical company seeded by Medicxi and focused on the development of novel antibody therapeutics for vitiligo. The deal could eventually be worth upwards of $1.4 billion. Its lead asset, auremolimab (VM6), an anti-IL-15Rβ monoclonal antibody (mAb), is expected to enter clinical development in […]

October 3, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 29 Sep 2022

Treatment for adults with chronic skin condition approved by FDA

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adult patients with prurigo nodularis. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab has been studied across more than 60 clinical trials involving more than 10,000 patients with various chronic diseases […]

September 29, 2022 - 4 minutesmins - By Liza Laws

News and Trends 19 Sep 2022

Kamari Pharma raises $8M in investment for development of drugs for skin diseases

An $8 million investment has been raised by Kamari Pharma following investment from the Guangzhou-Israel Biotechnology Fund (GIBF) that creates added value for Israeli, European and American companies looking to expand in China. Kamari Pharma was established at the end of 2018 by the leading Israeli based biotechnology funds Pontifax and Arkin Bioholdings. Prior to […]

September 19, 2022 - 3 minutesmins - By Liza Laws

News and Trends 16 Sep 2022

Regeneron and Sanofi announce published trial results in children with dermatitis

Positive results from a phase 3 trial in children aged 6 months to five years old with uncontrolled moderate-to-severe dermatitis have been published. Regeneron Pharmaceuticals, Inc. and Sanofi made the announcement today (September 16) that the Lancet published details on the success of Dupixent (dupilumab). These data were the basis for the U.S. Food and […]

September 16, 2022 - 3 minutesmins - By Liza Laws

News and Trends 13 Sep 2022

Ilya Pharma partners with US Defense Department for wound healing drug

A drug to accelerate wound healing and reduced scar volume has had a major breakthrough shown in results from a first in human trial. Ilya Pharma, a clinical stage immunotherapy company presented the findings at the US Defense Department’s (DoD) Military Health System Research Symposium (MHSRS) Conference in Florida and made the announcement yesterday (September […]

September 13, 2022 - 3 minutesmins - By Liza Laws

News and Trends 12 Sep 2022

Treatment for adults with moderate to severe psoriasis approved by FDA

A treatment for adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy has been approved by the U.S. Food and Drug Administration (FDA). Bristol Myers Squibb made the announcement today (September 12) that its allosteric tyrosine kinase 2 (TYK2) inhibitor, Sotyku (deucravacitinib) had been approved based on results from a phase […]

September 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 8 Sep 2022

Lutris Pharma radiation trial brings positive results for breast cancer patients

Top line results from a clinical trial treating breast cancer patients with radiation dermatitis (RD) have been positive. Lutris Pharma, based in Israel, is a biopharma company focused on improving cancer therapies. It announced its results from the open label part 1 and double blinded part 2 of it phase 1/2 trial yesterday (September 7). […]

September 8, 2022 - 4 minutesmins - By Liza Laws

News and Trends 8 Sep 2022

Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M

Arcutis Biotherapeutics, Inc. has entered into an agreement to acquire Ducentis BioTherapeutics Ltd., a privately held, preclinical-stage biotechnology company focused on developing novel therapies for inflammation and autoimmune diseases. Arcutis BioTherapeutics will acquire the outstanding shares of Ducentis for an upfront cash payment of approximately $16 million and Arcutis stock valued at approximately $14 million, […]

September 8, 2022 - 4 minutesmins - By Jim Cornall

News and Trends 2 Sep 2022

Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug

More than half of patients treated for psoriasis with an intravenous injection showed no visible pustules just one week after receiving treatment. Boehringer Ingelheim announced today (September 2) that the U.S. Food and Drug Administration (FDA) has approved the first treatment option, SPEVIGO, for generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is a novel, […]

September 2, 2022 - 2 minutesmins - By Liza Laws

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Skin disease

New Replay HSV gene therapy company Telaria to focus on skin diseases

A new treatment for tackling epidermolysis bullosa

Prurigo nodularis treatment recommended for EU approval

Incyte to acquire Medicxi-backed Villaris Therapeutics to tackle vitiligo

Treatment for adults with chronic skin condition approved by FDA

Kamari Pharma raises $8M in investment for development of drugs for skin diseases

Regeneron and Sanofi announce published trial results in children with dermatitis

Ilya Pharma partners with US Defense Department for wound healing drug

Treatment for adults with moderate to severe psoriasis approved by FDA

Lutris Pharma radiation trial brings positive results for breast cancer patients

Arcutis Biotherapeutics acquires Ducentis BioTherapeutics in deal worth up to $400M

Psoriasis pustules disappear in over half of patients using Boehringer Ingelheim drug

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!